Authors reported a favorable post alloSCT outcome associated with TNFRSF14 aberrations that affect 40% of all FL patients.104 This is the first demonstration of how a specific tumor genetic lesion may affect the capacity of tumor cells to stimulate allogeneic T-cell immune responses, generating wider consequences for adoptive immunotherapy strategies. This evidence concerns the gene TNFRSF14 and neoplasm.